<article id="sc_page06" class="slide" data-ag-slide-name="sc_page06">
    <div class="basic">
      <h1 data-ag-editable="Main Title">Neulasta<sup>®</sup> significantly reduces the incidence of FN and other<br />
          FN-associated events vs placebo</h1>
        <!-- Content here -->


        <ul id="list">
            <li>Neulasta<sup>®</sup> reduced the risk of FN by 94% in patients with breast cancer receiving docetaxel<sup>[Vogel 2005]</sup></li>

        </ul>


        <!-- GRAPH -->
        <div id="sc_page06_graph2_holder" class="main_content_style">
            <img src="content/images/sc_page06/graph.png" width="700" height="300" data-ag-editable="  Graph 2 Background">
            <div id="cooper_2011_graph2_content">
                <h2 id="graph2_title_sc_page06" data-ag-editable="  Graph 2 Title">Incidence of FN, FN hospitalizations and use of IV anti-infectives on all 4 cycles</h2>
                <p id="graph2_legend1_sc_page06" data-ag-editable="  Graph 2 Legend 1">Neulasta<sup>®</sup> + docetaxel (n=463)</p>
                <p id="graph2_legend2_sc_page06" data-ag-editable="  Graph 2 Legend 2">Placebo + docetaxel (n=465)</p>
                <p id="P-value1" data-ag-editable="Variable value chart 1">P<0.001</p>
                <p id="P-value2" data-ag-editable="Variable value chart 2">P<0.001</p>
                <p id="P-value3" data-ag-editable="Variable value chart 3">P<0.001</p>
                <p id="chart2-value" data-ag-editable="Percent value chart 2">1%</p>
                <p id="footer-chart1" data-ag-editable="Footer legend chart 1">FN <br/> (primary endpoint)</p>
                <p id="footer-chart2" data-ag-editable="Footer legend chart 2">Hospitalization associated with FN <br/>(secondary endpoint)</p>
                <p id="footer-chart3" data-ag-editable="Footer legend chart 3">Use of IV anti-infectives associated <br/>with FN (secondary endpoint)</p>

                <p id="graph2_vertical_axis_title_sc_page06" data-ag-editable="  Graph 2 Vertical Axis Title">Patients (%)</p>
                <ul id="sc_page06_graph2_vertical_axis_value" data-ag-editable="  Graph 2 Vertical Axis Values">
                    <li>25</li>
                    <li>20</li>
                    <li>15</li>
                    <li>10</li>
                    <li>5</li>
                    <li>0</li>
                </ul>
                <p id="graph2_bottom_text_sc_page06" data-ag-editable="  Graph 2 Bottom Text">Adapted from Vogel CL <i>et al.</i> J Clin Oncol 2005; 23(6):1178-84</p>

            </div>
            <!-- FIRST CHART -->
            <div id="sc_page06_graph2_arrow1" style="height: 191px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="301" height="270" data-ag-editable="  Graph 2 Left Bar">
                <p id="sc_page06_graph2_bar1_text" data-ag-editable="  Graph 2 Bar 1 Value"><span>17%</span></p>
            </div>
            <div id="sc_page06_graph2_arrow2" style="height: 176px;">
                <img src="content/images/sc_page06/arrow.png" width="100" height="176" data-ag-editable="  Graph 2 Right Bar">
                <p id="sc_page06_graph2_bar2_text" data-ag-editable="  Graph 2 Bar 2 Value">-94%</p>
            </div>
            <div id="sc_page06_graph2_arrow3" style="height: 16px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="205" height="207" data-ag-editable="  Graph 2 Right Arrow">
                <p id="sc_page06_graph2_bar3_text" data-ag-editable="  Graph 2 Bar 3 Value"><span>0.66</span><sup>†</sup><br><br>P=0.04<br>[95% CI: 0.44-0.98]</p>
            </div>
            <!-- END FIRST CHART -->

            <!-- SECOND CHART -->
            <div id="sc_page06_graph2_arrow1-2" style="height: 158px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="301" height="270" data-ag-editable="  Graph 2 Left Bar">
                <p id="sc_page06_graph2_bar1_text-2" data-ag-editable="  Graph 2 Bar 1 Value"><span>14%</span></p>
            </div>

            <div id="sc_page06_graph2_arrow3-2" style="height: 16px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="205" height="207" data-ag-editable="  Graph 2 Right Arrow">

            </div>
            <!-- END SECOND CHART -->

            <!-- THIRD CHART -->
            <div id="sc_page06_graph2_arrow1-3" style="height: 113px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="301" height="270" data-ag-editable="  Graph 2 Left Bar">
                <p id="sc_page06_graph2_bar1_text-3" data-ag-editable="  Graph 2 Bar 1 Value"><span>10%</span></p>
            </div>

            <div id="sc_page06_graph2_arrow3-3" style="height: 23px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="205" height="207" data-ag-editable="  Graph 2 Right Arrow">
                <p id="sc_page06_graph2_bar3_text-3" data-ag-editable="  Graph 2 Bar 3 Value"><span>2%</span></p>
            </div>
            <!-- END THIRD CHART -->

        </div>
    </div>
    <!-- END GRAPH -->
    
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="sc_page06_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="References Title">Reference:</strong></p>
          <br />
          <div data-ag-editable="References List">
             <ol>
                <li> Vogel CL <i>et al.</i> First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23(6):1178-1184</li>

             </ol>
          </div>
          <p data-ag-editable="References Bottom Copy"></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>